BOSTON, March 4, 2026 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, allosteric small molecules that target natural regulatory ...
IRF5 program strengthens Kymera’s oral immunology pipeline with a complementary mechanism to expand into rheumatic and other autoimmune diseases with a potential best-in-class oral drug IRF5, a ...
Good morning and welcome to Kymera's Immunology Innovation Day, our virtual event to introduce our next immunology program, IRF5. I'm Justine Koenigsberg, Kymera's Head of Investor Relations. Please ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results